Full Press Release Details
CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming November 2026 conferences. Presentations and fireside chats will be delivered by Neil Warma, President and Chief Executive Officer. Members of the Company’s leadership team will be available for one-on-one meetings at the conferences.
Conference details below:
November 9-11: Guggenheim 3 rd Annual Healthcare Innovation Conference Location: Boston, MA Fireside chat: Tuesday, November 10, 2:30 p.m. ET, Wheeler Room Webcast link: Click Here
November 10-12: Stifel 2026 Healthcare Conference Location: New York, NY Presentation: Wednesday, November 11, 2:40 p.m. ET, Spellman Room Webcast link: Click Here
November 16-17: UBS Global Biopharma Conference Location: London, UK Presentation: Monday, November 16, 10 a.m. GMT Webcast link: Click Here
November 16-19: Jefferies Global Healthcare Conference Location: London, UK
November 16-19: Clinical Trials on Alzheimer’s Disease (CTAD) Conference Location: Boston, MA Poster presentation: Monday, Nov 16-Tues Nov 17th Poster title: Poster # P047, Interim Safety and Biomarker Analysis of PRECISE-AD* (*data previously presented on July 28, 2026)
November 30-December 2: 9th Annual Evercore Healthcare Conference Location: Miami, FL Fireside chat: Wednesday, December 2, 9:10 a.m. ET, Sevilla A Webcast link: Click Here
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS’ lead asset in Phase 1b development, PMN310, is a humanized IgG1 monoclonal antibody designed to selectively target only the toxic oligomers of amyloid-beta (AβOs), believed to be among the earliest and most damaging drivers of Alzheimer’s disease, while avoiding binding to amyloid plaques and vascular deposits. ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
Investor Relations Contact:
Carie Pierce, VP, Investor Relations & External Affairs